U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
- PMID: 28087644
- DOI: 10.1158/1078-0432.CCR-16-0712
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Abstract
On December 22, 2014, the FDA granted accelerated approval to nivolumab (OPDIVO; Bristol-Myers Squibb) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Approval was based on a clinically meaningful, durable objective response rate (ORR) in a non-comparative analysis of 120 patients who received 3 mg/kg of nivolumab intravenously every 2 weeks with at least 6-month follow-up in an ongoing, randomized, open-label, active-controlled clinical trial. The ORR as assessed by a blinded independent review committee per RECIST v1.1 was 31.7% (95% confidence interval, 23.5-40.8). Ongoing responses were observed in 87% of responding patients, ranging from 2.6+ to 10+ months. In 13 patients, the response duration was 6 months or longer. The risks of nivolumab, including clinically significant immune-mediated adverse reactions (imARs), were assessed in 268 patients who received at least one dose of nivolumab. The FDA review considered whether the ORR and durations of responses were reasonably likely to predict clinical benefit, the adequacy of the safety database, and systematic approaches to the identification, description, and patient management for imARs in product labeling. Clin Cancer Res; 23(14); 3484-8. ©2017 AACR.
©2017 American Association for Cancer Research.
Similar articles
-
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.Clin Cancer Res. 2017 Jul 15;23(14):3479-3483. doi: 10.1158/1078-0432.CCR-16-0714. Epub 2017 Jan 10. Clin Cancer Res. 2017. PMID: 28073844 Clinical Trial.
-
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18. Lancet Oncol. 2015. PMID: 25795410 Clinical Trial.
-
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.Clin Cancer Res. 2017 Oct 1;23(19):5666-5670. doi: 10.1158/1078-0432.CCR-16-0663. Epub 2017 Feb 24. Clin Cancer Res. 2017. PMID: 28235882 Clinical Trial.
-
Nivolumab: A Review in Advanced Melanoma.Drugs. 2015 Aug;75(12):1413-24. doi: 10.1007/s40265-015-0442-6. Drugs. 2015. PMID: 26220912 Review.
-
Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.Prescrire Int. 2016 Dec;25(177):289-292. Prescrire Int. 2016. PMID: 30758924 Review.
Cited by
-
Allogeneic stem cells engineered to release interferon β and scFv-PD1 target glioblastoma and alter the tumor microenvironment.Cytotherapy. 2024 Oct;26(10):1217-1226. doi: 10.1016/j.jcyt.2024.05.012. Epub 2024 May 17. Cytotherapy. 2024. PMID: 38852095
-
Regulatory mechanisms of PD-1/PD-L1 in cancers.Mol Cancer. 2024 May 18;23(1):108. doi: 10.1186/s12943-024-02023-w. Mol Cancer. 2024. PMID: 38762484 Free PMC article. Review.
-
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).J Immunother Cancer. 2024 Mar 13;12(3):e008638. doi: 10.1136/jitc-2023-008638. J Immunother Cancer. 2024. PMID: 38485184 Free PMC article. Clinical Trial.
-
Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy.3 Biotech. 2023 Dec;13(12):411. doi: 10.1007/s13205-023-03826-2. Epub 2023 Nov 21. 3 Biotech. 2023. PMID: 37997595 Review.
-
The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge.Front Immunol. 2023 Jul 25;14:1195476. doi: 10.3389/fimmu.2023.1195476. eCollection 2023. Front Immunol. 2023. PMID: 37559727 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials